T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to its Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 19,634,011 shares of Denali Therapeutics Inc. common stock as of September 30, 2026.
Key Highlights
- Aggregate beneficial ownership: T. Rowe Price Investment Management, Inc. reported beneficial ownership of 19,634,011 shares of Denali Therapeutics Inc. common stock.
- Percent of class: The reported holdings represent 12.3% of the class of securities.
- Sole voting power: The filing disclosed sole voting power over 18,904,392 shares.
- Sole dispositive power: The filer reported sole dispositive power over all 19,634,011 shares.
- Shared voting and dispositive power: Both shared voting power and shared dispositive power are reported as 0.
- Event date: The date of event requiring this filing is stated as September 30, 2026.
- Filer classification: T. Rowe Price Investment Management, Inc. is identified as an investment adviser (type IA), incorporated in Maryland.
T. Rowe Price Investment Management Discloses 19.6 Million Shares in Denali Therapeutics
According to the filing, T. Rowe Price Investment Management, Inc., headquartered at 1307 Point Street, Baltimore, MD 21231 and organized under the laws of Maryland, submitted Amendment No. 2 to its Schedule 13G regarding its holdings in Denali Therapeutics Inc. (NASDAQ:DNLI). The issuer, Denali Therapeutics Inc., is listed with its principal executive offices at 161 Oyster Point Blvd., South San Francisco, CA, 94080. The securities covered are shares of Denali Therapeutics common stock, with CUSIP number 24823R105.
The filing reports that as of September 30, 2026, T. Rowe Price Investment Management, Inc. beneficially owned 19,634,011 shares, representing 12.3% of the class. Of those shares, the filer reported sole voting power over 18,904,392 shares and sole dispositive power over the full 19,634,011 shares. No shared voting or dispositive power was reported. The filing identifies the filer as an investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E).
In the certification section, the filing states that "the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing also notes that T. Rowe Price Investment Management, Inc. "expressly denied" that the filing of the Schedule 13G constitutes an admission that it is the beneficial owner of the referenced securities. The statement was signed by Ellen York, Vice President, on November 16, 2026.
What Was Disclosed
T. Rowe Price Investment Management, Inc. filed Amendment No. 2 to Schedule 13G disclosing beneficial ownership of 19,634,011 shares, or 12.3%, of Denali Therapeutics Inc. common stock as of September 30, 2026, with sole voting power over 18,904,392 shares and sole dispositive power over all reported shares.



Please wait processing your request...